RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
| Deferred tax assets | $ 146,560 | ||
| Research and development | $ 363,350 | $ 797,112 | |
| Gain (Loss) on Investments | 180,000 | ||
| Revision of Prior Period, Reclassification, Adjustment [Member] | |||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
| Research and development | 792,612 | ||
| Gain (Loss) on Investments | $ (180,000) | ||
| Iveda Taiwan [Member] | |||
| New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
| Intercompany amount due | $ 200,000 | ||
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|